NY-ESO-1–targeted gene-modified T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NY-ESO-1–targeted gene-modified T cells, covering 2025-07-30 to 2025-07-30. Get the full timeline:
Most recent: Clinical Trial Update: Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 [Phase 1]